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Abstract We have recently reported that the urokinase-type
plasminogen activator (uPA) up-regulates the cell surface
expression of its own receptor (uPAR) in several cell types,
independently of its enzymatic activity. uPA has no effect on
kidney 293 cells which do not express uPAR and then cannot
bind uPA. Kidney cells, transfected with the coding region of
uPAR cDNA, express very large amounts of uPAR and respond
to uPA stimulation by regulating uPAR both at mRNA and
protein levels. uPA effect occurs also in the presence of the
transcriptional inhibitor dichloro-ribobenzimidazole, whereas it
is abolished by the protein synthesis inhibitor cycloheximide.
Moreover, uPA-dependent uPAR up-regulation correlates with
the increase of a complex between the coding region of uPAR
mRNA and an unknown cellular factor. We then propose that
uPA regulates uPAR expression at a post-transcriptional level,
by promoting the binding of uPAR mRNA to a stabilizing
factor. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The urokinase-type plasminogen activator (uPA) is a serine
protease which promotes extracellular matrix (ECM) degra-
dation by activating plasminogen to plasmin. uPA binds a
speci¢c cell surface receptor (uPAR) expressed in a wide vari-
ety of cells. uPAR consists of three di¡erent domains: the
uPA binding domain 1 (D1), the connecting domain 2 (D2)
and the cell-anchoring domain 3 (D3) [1,2]. uPAR, besides
uPA, binds also an extracellular matrix (ECM) component,
vitronectin (VN) [3], and the L-subunit of some integrins [4,5].
uPA activity is regulated by two speci¢c inhibitors: type-1
(PAI-1) and type-2 (PAI-2). PAI-1 competes with uPAR
and with speci¢c integrins for the binding to VN [6,7]. These
multiple interactions determine the capability of the di¡erent
components of the uPA-mediated plasminogen activation sys-
tem to regulate not only cell surface associated proteolysis but
also cell adhesion to the ECM, both events being required for
cell migration [1,2,8]. In the last few years, in fact, several
reports have shown that uPAR, upon binding uPA, is directly
involved in chemotaxis [9], cell adhesion and migration [8]. Its
role in these processes is not merely due to the physical inter-
action with di¡erent ligands but depends also on its capability
to transduce signals inside the cells, even though the signaling
mechanisms are still unclear, since uPAR is anchored to the
cell surface by a GPI tail [10].
uPAR expression can be regulated by tumor promoters,
cytokines, hormones and growth factors, both at transcrip-
tional and post-transcriptional levels [11^14]. The expression
of the uPAR gene can be regulated via Sp1, NFkB and AP-1
transcription factors by speci¢c motifs contained within the
¢rst 180 bp upstream of the transcriptional start site [15,16].
Recently, a post-transcriptional regulation of uPAR expres-
sion has also been described. uPAR mRNA, as well as the
mRNA of several cytokines and oncoproteins, contains func-
tional AU-rich elements (AREs) in the 3P-untranslated region
(UTR) [17,18]. AREs regulate mRNA degradation by binding
stabilizing or destabilizing transacting factors [19^23]; some
of these factors have been cloned and characterized. ARE-
mediated post-transcriptional regulation has been reported
also for other components of the plasminogen activation sys-
tem, such as uPA [24], PAI-1 [25] and PAI-2 [26]. uPAR
mRNA contains also another speci¢c sequence, within the
coding region (nucleotides 195^246), which is able to destabi-
lize mRNA upon binding to an unidenti¢ed protein [14].
Stability determinants have been identi¢ed also within the
coding region of few other mRNAs, such as L-tubulin, c-
fos, c-myc, MAT-K1 and, very recently, PAI-2 mRNAs [27^
31].
uPAR is overexpressed in several tumors, both on the cell
surface and in plasma [1,32^35] and plays a fundamental role
in tumor cell invasion and metastasis. The mechanism result-
ing in its high expression in malignant tumor cells has not
been elucidated. We have previously shown that uPA up-reg-
ulates uPAR expression in di¡erent cell types [36]. We now
investigate the mechanism underlying uPA-mediated regula-
tion of uPAR expression.
2. Materials and methods
2.1. Reagents
Mouse monoclonal antibodies R4 were kindly provided by Dr. G.
Hoyer-Hansen (Finsen Laboratory, Copenhagen, Denmark) and
uPAR cDNA by Dr. MP Stoppelli (IIGB, CNR, Naples, Italy).
Horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG
were from Bio-Rad (Richmond, CO, USA), polyclonal anti-actin anti-
body and 5,6-dichloro-1-L-D-ribobenzimidazole (DRB) from Sigma
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(St. Louis, MO, USA). Enhanced chemiluminescence (ECL) detection
kit was from Amersham International (Amersham, UK); lipofect-
amine, Trizol reagent, Superscript II (M-MLV reverse transcriptase
(RT)) and geneticin from Life Technologies (Gaithersburg, MD,
USA). Polyvinylidene £uoride (PVDF) ¢lters were from Millipore
(Windsor, MA, USA). PcDNA3 plasmid was from Invitrogen (San
Diego, CA, USA), the PCR kit from Perkin-Elmer (Branchburg, NJ,
USA) and T7 and Sp6 polymerases from Promega (Madison, WI,
USA).
2.2. Cell culture
293 human kidney cells were grown in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) (Gibco, Life Technologies, Gaithersburg, MD,
USA) supplemented with 10% fetal calf serum (FCS).
2.3. Inactivation of uPA
uPA was inactivated by 2 h incubation with 10 mM diisopropyl-
£uorophosphate (DFP) [37].
2.4. Western blot
Lung tissues and cells were lysed in 1% Triton X-100/PBS in the
presence of protease inhibitors (Sigma); the protein content was mea-
sured by a colorimetric assay (Bio-Rad). 30^50 Wg of cell lysate pro-
teins and 100 Wg of tissue extract proteins were electrophoresed on a
9% sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and transferred onto a PVDF membrane. The membrane was
blocked with 5% non-fat dry milk, and probed with R4 anti-uPAR
antibody, at a concentration of 1 Wg/ml. Finally, washed ¢lters were
incubated with horseradish peroxidase-conjugated anti-mouse anti-
body and detected by ECL. Some ¢lters were washed and reprobed
with rabbit anti-actin antibodies (1 Wg/ml).
2.5. Transfection
The coding region of uPAR cDNA (nt 33^1018) was cloned in the
EcoRI site of pcDNA3 and the resulting plasmid was named uPAR-
pcDNA3. 5U106 cells, cultured overnight in 100 mm tissue culture
dishes, were transfected with 10 Wg of uPAR-pcDNA3 or control
vector pcDNA3 and 60 Wl of lipofectamine for 5 h at 37‡C (5%
CO2). Transfected cells were selected by 1.5 mg/ml geneticin.
2.6. Reverse polymerase chain reaction
Total cellular RNA was isolated by lysing cells in Trizol solution
according to the supplier’s protocol. RNA was precipitated and quan-
titated by spectroscopy. 5 Wg of total RNA was reversely transcribed
with random hexamer primers and 200 U of M-MLV reverse tran-
scriptase. 1 Wl of reversely-transcribed DNA was then ampli¢ed using
uPAR-speci¢c 5P sense (CTG CGG TGC ATG CAG TGT AAG) and
3P antisense (GGT CCA GAG GAG AGT GCC TCC) 21-mer cDNA
primers or GAPDH-speci¢c 5P sense (TTC ACC ACC ATG GAG
AAG GCT) and 3P antisense (ACA GCC TTG GCA GCA CCA GT)
20-mer cDNA primers, as a control. Semi-quantitative polymerase
chain reaction (PCR) was performed for 25 cycles at 62‡C in a ther-
mocycler, and the reaction products were analyzed by electrophoresis
in 1% agarose gel containing ethidium bromide, followed by photog-
raphy under ultraviolet illumination.
2.7. In vitro transcription
1 Wg of linearized plasmid containing the coding region of human
uPAR was transcribed ‘in vitro’ with T7 RNA polymerase according
to the supplier’s protocol, in the presence of 50 WCi [K-32P]UTP.
Precipitation in 1 M NH4 acetate was performed to remove unincor-
porated radioactivity. The speci¢c activity of the product was 108
cpm/Wg. The size of labeled mRNA transcript was con¢rmed by elec-
trophoresis on a 5% urea gel.
Unlabeled RNA competitors were prepared by ‘in vitro’ transcrip-
tion of 10 Wg of the linearized plasmid, according to the supplier’s
protocol, using T7 RNA polymerase for sense uPAR mRNA and SP6
RNA polymerase for antisense uPAR mRNA.
2.8. Gel mobility shift assay
Gel mobility shift assay was performed as previously described [14].
50 Wg of cell lysate proteins or 20 Wg of tissue extract proteins was
incubated with 4U105 cpm of 32P-labeled transcript in a mixture
containing 15 mM KCl, 5 mM MgCl2, 0.25 mM EDTA, 0.25 mM
dithiothreitol, 12 mM HEPES (pH 7.9), 10% glycerol and 200 ng/Wl of
Escherichia coli tRNA in a total volume of 20 Wl at 30‡C for 30 min.
The mixture was then treated with 50 U of RNase A at 37‡C for 30
min and with 5 mg/ml of heparin at room temperature for 10 min to
avoid non-speci¢c protein binding. Samples were ¢nally analyzed by
5% native PAGE and autoradiography.
3. Results
3.1. uPA increases uPAR expression in uPAR-transfected cells
We have previously shown that inactive uPA up-regulates
cell surface expression of its receptor in several cell types ex-
cept in kidney 293 cells which do not express uPAR and then
cannot bind uPA [36]. uPAR expression can be regulated
transcriptionally, by speci¢c motifs contained in the promoter
region of the uPAR gene [15,16], or post-transcriptionally, by
determinants present within the 3P untranslated region and in
the coding region of uPAR mRNA [14,17,18]. We then stably
transfected only the coding region of uPAR cDNA in 293
cells in order to investigate its role in the uPA-mediated reg-
ulation of uPAR expression at protein and mRNA levels.
293 cells, transfected with uPAR cDNA (uPAR-293, Fig. 1,
Fig. 1. uPA regulates uPAR expression in uPAR-transfected cells.
293 cells were stably transfected with pcDNA3 vector (V-293, lanes
1, 2) or with the coding region of uPAR cloned in pcDNA3
(uPAR-293, lanes 3, 4, 5, 6). Upper panel: transfected cells were
treated with (lanes 2, 4) or without (lanes 1, 3) 5 nM DFP-uPA for
16 h at 37‡C and lysed in 1% Triton X-100. 5 Wg of total proteins
of V-293 and uPAR-293 cell lysates was analyzed by 9% SDS^
PAGE and Western blot with 1 Wg/ml of an anti-uPAR monoclonal
antibody. Lower panel: uPAR-293 cells were treated with (lane 6)
or without (lane 5) 5 nM DFP-uPA for 16 h at 37‡C and lysed in
Trizol. Total RNA was prepared, reverse-transcribed and ampli¢ed
by 25 cycles PCR using primers for uPAR or for GAPDH, as a
control for DNA loading. Bu¡er (lane 7) and 10 ng of uPAR-
cDNA (lane 8) were ampli¢ed as a negative and a positive control,
respectively. PCR products were analyzed by electrophoresis in 1%
agarose gel containing ethidium bromide, followed by photography
under ultraviolet illumination. The levels of uPAR mRNA in lanes
5, 6 were estimated by densitometric scanning and normalized
against GAPDH loading controls.
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upper panel, lanes 3, 4) or with the pcDNA3 vector alone (V-
293, Fig. 1, upper panel, lanes 1, 2) as a control, were treated
with (lanes 2, 4) or without (lanes 1, 3) 5 nM DFP inactivated
uPA for 16 h at 37‡C. uPA was inactivated in these and in all
the following experiments in order to observe only the e¡ects
mediated by its interaction with uPAR, thus excluding those
due to its enzymatic activity. Cells were then lysed and ana-
lyzed by 9% SDS^PAGE and Western blot using an anti-
uPAR monoclonal antibody (upper panel, lanes 1^4).
uPAR-transfected 293 cells synthesized a large amount of re-
ceptor, which increased after uPA treatment (lanes 3, 4). As
expected, control cells V-293 did not express uPAR even after
uPA treatment (lanes 1, 2). In this experiment a very small
amount of total proteins (5 Wg) was analyzed, since uPAR-293
cells express huge amounts of uPAR, therefore the same ¢lters
could not be hybridized with actin, as a control for protein
loading; however, 30 Wg of the same samples was analyzed by
Western blot with anti-actin antibodies, showing the same
total protein concentration (not shown).
We then investigated if the observed increase in uPAR ex-
pression correlated with the increase in uPAR mRNA by
semi-quantitative RT-PCR and densitometric scanning (Fig.
1, lower panel). uPAR-293 cells were treated with (lane 6) or
without (lane 5) 5 nM DFP-uPA for 16 h at 37‡C and lysed.
Total RNA was prepared, reverse-transcribed and ampli¢ed
by 25 cycles PCR in the presence of primers for uPAR or for
GAPDH as a loading control (lanes 5, 6). Bu¡er (lane 7) or
uPAR cDNA (lane 8) were ampli¢ed as negative and positive
controls, respectively. The analysis of PCR products by aga-
rose gel showed the presence of uPAR mRNA in uPAR-trans-
fected cells (lane 5) and its three-fold increase after treatment
with DFP-uPA (lane 6), thus demonstrating that the uPA-
mediated increase of uPAR expression observed by Western
blot analysis was due to the increase of the speci¢c uPAR
mRNA.
These results indicate that the expression of uPAR cDNA
lacking 3P regulatory untranslated regions and under the con-
trol of a viral promoter (CMV) can still be regulated by uPA.
3.2. uPA regulates uPAR expression at a post-transcriptional
level in uPAR-transfected cells
uPA could regulate uPAR expression in uPAR-293 cells at
a transcriptional level, by activating the CMV promoter or at
a post-transcriptional level, by promoting uPAR mRNA sta-
bilization. To test the ¢rst hypothesis, uPAR-293 were tran-
siently transfected with the cDNA of an unrelated protein, the
37 kDa precursor of the laminin receptor (37LR), provided
with a T7-tag tail and cloned in pcDNA3, under the control
of the CMV promoter, as in the case of uPAR cDNA. Double
transfected cells were treated with 5 nM DFP-uPA, then lysed
and analyzed by 9% SDS^PAGE and Western blot with anti-
uPAR, anti-T7-tag and anti-37LR antibodies (Fig. 2). West-
ern blot with anti-uPAR antibodies (panel A) showed that
uPA up-regulates uPAR expression also in uPAR-293 cells
transfected with 37LR-cDNA or with the vector alone, as a
control (Fig. 2A, lanes 2, 4). Western blot with anti-T7-tag
and anti-37LR antibodies (Fig. 2B and C, respectively)
showed that, in the same cells, uPA did not increase the ex-
pression of tagged 37LR (B and C, lanes 2). Endogenous
37LR, as expected, was not modulated by uPA (Fig. 2C, lanes
2, 4). These experiments indicate that uPA does not induce
activation of the CMV promoter which controls both uPAR
and 37LR cDNA transcription in double transfected 293 cells.
We then examined the e¡ect of uPA on uPAR mRNA
stability, to test the hypothesis of a post-transcriptional mech-
anism of regulation (Fig. 3). Firstly, we analyzed the decay
curve of uPAR mRNA in uPAR-293 cells by adding the tran-
scription inhibitor DRB and harvesting RNA at various time
points (upper panel). Semi-quantitative RT-PCR analysis of
RNA and densitometric scanning showed 40% and 80% of
uPAR mRNA degradation after 8 and 16 h of 0.1 mM
DRB treatment, respectively (Fig. 3, upper panel, lanes 4, 5).
We then compared uPAR mRNA decay in DFP-uPA-
treated or untreated uPAR-293 cells (Fig. 3, lower panel).
Cells were stimulated with (lower panel, lanes 2, 4) or without
(lower panel, lanes 1, 3) 5 nM DFP-uPA for 16 h at 37‡C, in
order to allow the induction of the initial transcripts, and then
arrested transcriptionally with DRB for 16 h. Semi-quantita-
tive RT-PCR analysis of total RNA and densitometric scan-
ning showed that in the absence of uPA, uPAR mRNA was
decreased to the same extent as in the upper panel, whereas
uPA-induced up-regulation of uPAR mRNA was maintained
also in the absence of transcription (Fig. 3, lower panel, lanes
3, 4), thus con¢rming a post-transcriptional regulation. There-
fore, the observed uPA-dependent increase of uPAR mRNA
was due to the increased stability of the mRNA and not to
neosynthesis.
Fig. 2. uPA does not up-regulate uPAR expression in uPAR-293
cells through a transcriptional mechanism. uPAR-293 cells were
transiently transfected with the cDNA of 37LR cloned into
pcDNA3 (lanes 1, 2) or with the vector alone (lanes 3, 4). Cells
were treated with (lanes 2, 4) or without (lanes 1, 3) 5 nM DFP-
uPA for 16 h at 37‡C and lysed. 1 Wg (A) or 30 Wg (B, C) of total
proteins was analyzed by 9% SDS^PAGE and Western blot with
anti-uPAR (A), anti-tag (B) and anti-37LR (C) antibodies. Filters B
and C were hybridized with anti-actin polyclonal antibodies as a
control for protein loading; actin was undetectable in ¢lter A where
1 Wg of total proteins was loaded.
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3.3. Post-transcriptional mechanism of uPA-mediated
regulation of uPAR expression in uPAR-transfected cells
To investigate the regulatory mechanism involved in uPAR
mRNA stability, we examined whether the uPAR mRNA
binds to transacting factor(s). We used a gel mobility shift
assay to detect transacting factor(s), conferring lability or
stability on uPAR mRNA in uPAR-293 cells. Total lysates
of cells treated with or without 5nM DFP-uPA for 16 h were
incubated with 32P-labeled uPAR mRNA and treated with
RNase A. The analysis on a 5% non-denaturing polyacryl-
amide gel (Fig. 4, upper panel) showed a single RNase resis-
tant RNA^protein complex in unstimulated cells (lane 1); this
complex was up-regulated by uPA treatment (lane 2). Binding
of labeled uPAR mRNA was competed by a 100-fold excess
of cold sense uPAR mRNA (lanes 3, 4), whereas it was not
a¡ected by cold antisense uPAR mRNA (lanes 5, 6). Labeled
uPAR mRNA was not protected from RNase action in the
absence of cell lysate (lane 7). Densitometric scanning showed
a three-fold increase of the complex in uPA-treated cells as
compared to untreated cells (Fig. 4, lower panel). These re-
sults indicate that the coding region of uPAR mRNA is able
to bind speci¢cally a cellular factor present in uPAR-293 cells
Fig. 3. uPA promotes the stability of uPAR mRNA. Upper panel: uPAR-293 cells were treated with 0.1 mM DRB in the absence of serum,
and lysed after 0, 2, 4, 8 and 16 h. Lower panel: uPAR-293 cells were incubated with (lanes 2, 4) or without (lanes 1, 3) 5 nM DFP-uPA for
16 h at 37‡C and then with 0.1 mM DRB (lanes 3, 4) or bu¡er (lanes 1, 2) for further 16 h and lysed. Total RNA was reverse-transcribed and
ampli¢ed by 25 cycles PCR using primers for uPAR or for GAPDH, as a control for DNA loading. PCR products were analyzed by electro-
phoresis in 1% agarose gel containing ethidium bromide, followed by photography under ultraviolet illumination. The levels of uPAR mRNA
were estimated by densitometric scanning and normalized against GAPDH loading controls.
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and that uPA up-regulates the formation of the resulting
mRNA^protein complex. Therefore, the increased level of
the complex could be related to the increased stability of
uPAR mRNA induced by uPA.
3.4. Cycloheximide abrogates uPA-mediated up-regulation of
uPAR expression in uPAR-transfected cells
uPA stimulation of uPAR-293 cells was also performed in
the presence of cycloheximide, an inhibitor of protein synthe-
sis, in order to investigate if uPA promotes the synthesis of
factors involved in the increased stability of uPAR mRNA
(Fig. 5). uPAR-293 cells were treated with (lanes 2, 4) or
without (lanes 1, 3) 5 nM DFP-uPA for 6 h in the presence
(lanes 3, 4) or in the absence (lanes 1, 2) of 10 Wg/ml cyclo-
heximide and lysed. Semi-quantitative RT-PCR analysis of
total mRNA showed that 6 h of DFP-uPA treatment were
su⁄cient to increase uPAR mRNA in uPAR-293 cells (lanes
1, 2). However, uPA, in the presence of cycloheximide, was
not able to increase uPAR mRNA (lanes 3, 4), thus indicating
that uPA e¡ect requires protein synthesis.
4. Discussion
uPAR and its ligand uPA have been implicated in several
pathological and physiological processes which require cell
migration, such as tumor cell invasion and metastasis. En-
hanced expression of uPAR has been described in several
types of tumor, both on the cell surface and in plasma
[1,32^35]. Therefore, it should be expected that the expression
of uPAR is strictly controlled. In fact, uPAR expression can
be regulated by various agents, which appear to act at both
transcriptional and post-transcriptional levels. We have pre-
viously shown that uPA, upon binding uPAR, is able to in-
crease the expression of its receptor on the cell surface of
di¡erent cell types [36]. The same observation has been re-
ported in a breast carcinoma cell line [38] ; in this report, a
correlation was also found between the levels of uPA and
uPAR and the activity of the transcriptional factor Sp1 in
breast carcinoma tissues, thus suggesting that uPA regulates
uPAR expression at a transcriptional level, by increasing the
activity of the transcriptional factor Sp1. We then investigated
if uPA can also act at a post-transcriptional level, like other
agents (PMA, TGFL, etc.), showing that uPA can modulate
uPAR expression in cells transfected only with the coding
region of the receptor under the control of a viral promoter,
which is not activated by the enzyme. The arrest of transcrip-
tion did not a¡ect the uPA capability of regulating uPAR
expression, thus proving that uPA can act not only at a tran-
scriptional level but also at a post-transcriptional level, by
promoting uPAR mRNA stability. The increase in uPAR ex-
pression induced by uPA requires protein synthesis and cor-
Fig. 4. uPA up-regulates a uPAR mRNA^protein complex, identi-
¢ed by gel mobility shift assay, in uPAR-293 cells. Cells were
treated with (lanes 2, 4, 6) or without (lanes 1, 3, 5) 5 nM DFP-
uPA for 16 h and lysed. 50 Wg of total proteins was incubated with
32P-labeled uPAR mRNA in the absence of a competitor (lanes 1,
2), in the presence of a 100-fold excess of cold sense uPAR mRNA
(lanes 3, 4) or cold antisense uPAR mRNA (lanes 5, 6). The mix-
tures and the probe alone, as a control (lane 7), were then treated
with RNase A and analyzed by 5% non-denaturing polyacrylamide
gel and autoradiography. The arrow indicates the RNA^protein
complex. Lower panel: The levels of uPAR mRNA^protein complex
were estimated by densitometric scanning.
Fig. 5. Cycloheximide abrogates uPA-mediated up-regulation of
uPAR expression in uPAR-transfected cells. uPAR-293 cells were
treated with (lanes 2, 4) or without (lanes 1, 3) 5 nM DFP-uPA for
6 h in the presence (lanes 3, 4) or in the absence (lanes 1, 2) of 10
Wg/ml cycloheximide. Total RNA was reverse-transcribed and ampli-
¢ed by 25 cycles PCR using primers for uPAR or for GAPDH, as
a control for DNA loading. PCR products were analyzed by elec-
trophoresis in 1% agarose gel containing ethidium bromide, fol-
lowed by photography under ultraviolet illumination. The levels of
uPAR mRNA were estimated by densitometric scanning and nor-
malized against GAPDH loading controls.
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relates with the increase in a uPAR mRNA^protein complex.
All together these observations suggest that uPA is able to
regulate uPAR expression at a post-transcriptional level by
promoting the binding of the coding region of uPAR
mRNA to a stabilizing factor. We do not know, at the mo-
ment, if uPA induces neosynthesis of this factor or activates a
mechanism which renders an already present factor free to
bind uPAR mRNA. Whichever is the mechanism, uPA,
upon binding to uPAR, is able to activate cell signaling
even though the receptor lacks a transmembrane and intra-
cytoplasmic domain [10].
The presence in the mRNA coding region of sequences
regulating mRNA stability has been described only in few
other cases [27^31]. It has been reported that c-myc contains
a destabilizing sequence in the message that can be inactivated
by a 75 kDa stabilizing protein [29]; the same mechanism
could also occur in uPA-dependent uPAR mRNA stabiliza-
tion.
A regulatory determinant has been described also in the
coding region of uPAR mRNA (nt 195^246); this determinant
is able to bind an as yet uncharacterized cytoplasmic protein
which appears to destabilize uPAR mRNA in human meso-
thelioma cells [14]. This ¢nding is not in contrast with our
observation. Indeed, it is possible that the same determinant
binds both stabilizing and destabilizing regulatory proteins,
such as the regulatory determinants (AREs) present in the
untranslated region (UTR) of several mRNAs [19^23]. The
identi¢cation of the binding site for the stabilizing factor
will elucidate this point.
Investigations on the occurrence ‘in vivo’ of the regulatory
mechanism observed in uPAR-transfected 293 cells will eluci-
date its importance in the uPA-uPAR-dependent invasiveness
of metastatic cells.
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